PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma

Leukemia Research
Rodrigo Proto-SiqueiraMarco A Zago

Abstract

The preferentially expressed antigen in melanoma (PRAME) gene is aberrantly expressed in chronic lymphoproliferative disorders (CLD). We produced and characterized an anti-PRAME monoclonal antibody (MoAb), which was then applied in a quantitative flow cytometric (QFC) method to evaluate PRAME expression in leukemic cells from the peripheral blood (PB) of 47 patients with chronic lymphocytic leukemia and seven with mantle cell lymphoma as well as in the PB mononuclear cells (PBMCs) and B lymphocytes from 15 healthy subjects. Approximately 90% of CLD, but none of the normal samples, presented more than 20% of PRAME+ lymphocytes. Moreover, the intensity of PRAME expression was significantly higher in CLD cells compared to normal B lymphocytes and PBMCs. By immunofluorescence microscopy and by permeabilized flow cytometry we demonstrated that PRAME is a membrane antigen and a cytoplasmic protein aberrantly expressed in malignant CLD. Our results suggest that the analysis of PRAME protein may contribute for the distinction between normal and leukemic cells in CLD, and that PRAME may be a potential target for therapy.

References

Jun 10, 1998·Experimental and Clinical Immunogenetics·A F KirkinJ Zeuthen
Apr 12, 2001·British Journal of Haematology·M MatsushitaY Kawakami
Feb 2, 2002·Nature·Laura J van 't VeerStephen H Friend
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Nov 7, 2002·Cancer Genetics and Cytogenetics·Daniel SteinbachBernd Gruhn
Jul 9, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·André OberthuerMatthias Fischer

❮ Previous
Next ❯

Citations

Jul 13, 2007·Breast Cancer Research and Treatment·Padraig DoolanLorraine O'Driscoll
Mar 2, 2011·International Journal of Hematology·Adam J LinleyRobert C Rees
Sep 15, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·Ulrike GerdemannAnn M Leen
Apr 11, 2008·Leukemia Research·Semra Paydas
Feb 26, 2008·Leukemia Research·Evgeny AronsRobert J Kreitman
Mar 7, 2012·Biochemical and Biophysical Research Communications·Pingxian TanJingnian Shen
Apr 15, 2017·The Cancer Journal·David A Braun, Catherine J Wu
Dec 7, 2010·American Journal of Hematology·Jonathan M GerberRichard J Jones
Oct 11, 2017·British Journal of Haematology·Francesca MestichelliPiero Galieni
Jan 29, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Spyridoula VasileiouGeorge Carrum

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.